It has been experimentally proven that iguratimod affects Act1, which leads to an Act1-IKKi-TRAF5 gene pathway-induced disturbance of IL-17 in RA fibroblast-like synoviocytes. This evidence concerns the gene IL17A and rheumatoid arthritis.